Drug Profile
Research programme: cancer therapeutics - Gyre Therapeutics/Pfizer
Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Catalyst Biosciences; Wyeth
- Developer Catalyst Biosciences; Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 10 Jan 2014 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 15 Oct 2009 Wyeth has been acquired by Pfizer